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Background: Suicidal ideation (SI) is a cardinal aspect of major depressive disorder 
(MDD); however, patient-reported outcomes data from large-scale surveys are limited con-
cerning SI in the context of MDD. This study aims to understand the association between 
varying levels of SI and health-related quality of life (HRQoL), work productivity, healthcare 
resource utilization (HRU), and associated costs in patients with moderately severe/severe 
MDD.
Methods: This was a retrospective, cross-sectional analysis of 2013 national survey data. 
Patients who self-reported moderately severe or severe MDD and completed the Short 
Form Survey Version 2 (SF-36v2), Work Productivity Loss and Activity Impairment 
questionnaire (WPAI), and questions related to HRU were analyzed. Direct and indirect 
costs were calculated. Patients were categorized and analyzed by the level of SI (no SI, 
low, moderate, and high) based on their response to Item 9 of the Patient Health 
Questionnaire-9.
Results: Among 75,000 respondents, 15.3% self-reported receiving a physician diagnosis 
of moderately severe or severe MDD and 2.8% of the total sample endorsed some level 
of SI. Patients with high SI showed a higher burden than patients with no SI, reporting 
lower mean SF-36v2 mental component summary scores (p<0.001), higher work produc-
tivity loss (p=0.039), and higher numbers of per patient per month hospitalizations 
(p=0.002) and emergency room visits (p=0.011). High SI was associated with greater 
per patient per month direct costs ($1220 vs $796; p=0.002) and indirect costs ($1449 vs 
$1058; p=0.001) compared with no SI. When patients with low or moderate SI were 
compared with patients with no SI, the results were mixed.
Conclusion: Higher levels of SI were associated with lower HRQoL, greater HRU, and 
more work impairment resulting in higher direct and indirect costs compared with 
patients with MDD but no SI. These results highlight the need to implement effective 
treatment models and interventions in the employed population.
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Introduction
Major depressive disorder (MDD) is a common, serious 
mood disorder with symptoms lasting for ≥2 weeks that 
can vary from mild to severe and affect feelings, thoughts, 
and daily activities.1,2 Depression is the leading cause of 
disability worldwide3,4 and is associated with significant 
health-related quality of life (HRQoL) impairment and 
economic burden.5–8 In 2018, an estimated 17.7 million 
adults in the United States (US) had at least 1 major 
depressive episode in the past year, representing approxi-
mately 7.2% of the adult population;9 the lifetime preva-
lence rate of major depressive episodes in the US has been 
estimated to be as high as 20.6%.10 The incremental eco-
nomic burden of MDD in the US is considerable; in 2010, 
it was approximately $210.5 billion.7 This burden varies 
by the severity of depression symptoms; in a study of 
adults with treatment-resistant MDD, all-cause total 
healthcare costs, adjusted for baseline characteristics, 
were significantly greater for patients with moderate and 
severe depression symptoms relative to those with mild 
symptoms ($3455 and $5150 per patient per year, 
respectively).8
Suicidal ideation (SI) is a cardinal aspect of MDD.11 
The link between MDD and suicide has been well 
established,12 with an estimated 31% of US adults with 
MDD experiencing past-year SI in 2017 (an increase from 
26% in 2009).13 Suicide-related costs among patients with 
MDD are substantial; such costs were estimated to be $9.7 
billion in the US in 2010, which was approximately 5% of 
the total incremental economic burden of adults with 
MDD.7
In the overall US population, suicide rates have been 
increasing,14 and MDD is among the most prevalent con-
ditions associated with SI and suicidal behavior.15 While 
the humanistic and economic burden of MDD and SI have 
been investigated individually,5–8,16,17 less is known about 
the association between SI and the burden experienced by 
patients with MDD. The serious nature of SI suggests that 
its presence could lead to reduced HRQoL and increased 
economic burden. However, levels of SI vary across a 
spectrum and detecting its presence can be difficult. 
Moreover, the effect of SI could be subtle, such as decreas-
ing work productivity or increasing utilization of acute 
care services. Given these potential challenges, the current 
study employed a broad, US-based survey that collected 
data from the Patient Health Questionnaire-9 (PHQ-9) to 
provide important insights into this patient population. The 
PHQ-9, a patient self-reported instrument, is aligned with 
the Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition symptom criteria for MDD and has been 
validated as a useful tool for the screening of depressive 
disorders and as a reliable and valid measure of depression 
symptom severity.18,19 Additionally, it has been shown to 
have a high sensitivity to identify patients who are at 
increased risk for suicide attempt or death over a range 
of risk levels.20–23
In the current study, we evaluated HRQoL, work pro-
ductivity, healthcare resource utilization (HRU), and eco-
nomic burden for patients with a diagnosis of moderately 
severe or severe MDD by increasing levels of SI in an 




This was a retrospective, cross-sectional study that used 
the US National Health and Wellness Survey (NHWS), a 
self-report survey of the US adult population. The NHWS 
is a large, yearly, general health survey of US adults (18+ 
years). The survey instrument and study procedures used 
in the survey were reviewed and approved by the Essex 
Institutional Review Board (Lebanon, NJ). All participants 
provided informed consent. For the current study, data 
from the 2013 US NHWS (N=75,000) were used.
Sample
Adult patients who self-reported a physician diagnosis of 
depression and a score of ≥15 on the PHQ-924 were 
categorized as having moderately severe or severe MDD 
and were included in the analysis. PHQ-9 scores of 5, 10, 
15, and 20 were previously identified as valid and respon-
sible thresholds for the lower limits of mild, moderate, 
moderately severe, and severe depression, respectively, 
and scores of ≥15 were shown to be highly specific in 
predicting the presence of major depression.18 Patients 
who screened positive on the mood disorder questionnaire 
(MDQ) were excluded. The MDQ is a screening tool used 
to evaluate potential bipolar disorder.25 Both the PHQ-9 
and MDQ criteria were used to ensure that the study 
population specifically had MDD. Furthermore, as HRU 
and cost burden increase with increasing MDD severity,8 
the population with more severe MDD is of particular 
interest to clinicians and researchers.
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Measures
Levels of Suicidal Ideation
Levels of SI were assessed using Item 9 of the PHQ-9.24 
Increasing scores on this item have been shown to be 
associated with a higher risk of suicide in short- and 
long-term follow-up.20,22,23 Patients responded to the 
question: “Over the past 2 weeks, how often have you 
been bothered by thoughts that you would be better off 
dead or of hurting yourself in some way?” Patients who 
scored 0 (not at all) were categorized as ‘no SI: depressed 
but without SI’; patients who scored 1 (several days), 2 
(more than half the days), or 3 (nearly every day) were 
categorized as ‘low SI’, ‘moderate SI’, and ‘high SI’, 
respectively. Based on previous research,22 we expected 
to find a stepwise increase in the associated burden as 
PHQ-9 Item 9 scores increase.
Patient Demographic and Clinical Characteristics
Demographic characteristics collected from each respondent, 
including age, gender, race/ethnicity, marital status, educa-
tion, employment status, household income, type of health 
insurance, and census region based on zip code, were used to 
characterize the patients. Further, the following clinical char-
acteristics were also characterized: body mass index (BMI), 
cigarette smoking, alcohol consumption, exercise, self- 
reported physical and mental comorbidities associated with 
depression, and Charlson comorbidity index.26
Depression-Specific Measures
Respondents meeting the criteria for the MDD module of 
the survey completed additional depression-specific vari-
ables, including a family history of depression, length of 
diagnosis, whether the individual participated in talk ther-
apy (yes/no), current medication(s) class(es), who pre-
scribed the medication(s), and number of months on 
current medication. These variables were included to 
explore associations with patients’ level of SI.
Health-Related Quality of Life
Patients’ HRQoL was measured by the Short Form 
Survey Version 2 (SF-36v2).27 The SF-36v2 is a 36- 
item general validated measure of HRQoL across multi-
ple populations.28 The measure was scored as two sum-
mary scores (physical [PCS] and mental [MCS] 
component summary scores) and as eight specific sepa-
rate domain scores (see Appendix Table 1 and Appendix 
Table 2 for domain scores). These metrics were normed 
such that the population mean for PCS and MCS is 50. 
The minimal important difference (MID), or the smallest 
difference that a clinician would regard as important, is 
3 points for PCS and MCS and 5 points for the eight 
health domain scales.29 The Short Form-6 Dimension 
(SF-6D) health utilities index was calculated using SF- 
36v2 items. Scores on the SF-6D range from 0 (death) 
to 1 (perfect health), and the general population mean 
score has been found to be 0.79–0.81 among a repre-
sentative sample of UK respondents30 and 0.76–0.80 
among US respondents.31 A MID of 0.041 points has 
been reported for the SF-6D.32
Work Productivity Loss and Activity Impairment
Work productivity loss and activity impairment in the past 
week was assessed by the 6-item Work Productivity Loss 
and Activity Impairment questionnaire (WPAI).33 The 
WPAI is a validated general measure widely used across 
several populations.34 This measure assesses presenteeism 
(time not productive while at work), absenteeism (time 
absent from work), and activity impairment (% of impair-
ment in daily activities due to health). The overall work 
impairment was scored based on the aggregated absentee-
ism and presenteeism scores. Scores on the WPAI repre-
sent the percentage of time impaired in the past 7 days. 
Only respondents who were employed full- or part-time 
responded to the presenteeism and absenteeism questions.
Healthcare Resource Utilization
NHWS data include the number of traditional healthcare 
provider (HCP) visits (eg, general practitioner, internist, 
psychiatrist), number of hospitalizations, and number of 
ER visits respondents report having in the last 6 months. 
Using these data, mean utilization rates for patients with 
each level of SI were calculated for the 6-month recall 
period and then divided by 6 to estimate the mean per 
patient per month (PPPM) utilization.
Direct and Indirect Costs
The cost for an average HCP visit, hospitalization, and ER 
visit were obtained from the 2013 Medical Expenditure 
Panel Survey (MEPS) data.35 The 2013 mean values (US 
dollars) for each HRU type were: ER visit ($939), hospi-
talization ($13,097), and HCP visit ($200). To calculate 
mean PPPM direct costs for each HRU type, for each level 
of SI, the mean PPPM utilization rates were multiplied by 
the mean cost for the corresponding type of HRU.
Indirect costs were calculated based on responses to the 
WPAI for each employed respondent and by using 2013 
median weekly income figures obtained from the Bureau 
of Labor Statistics.36 For each respondent, an hourly rate 
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was estimated by dividing the median weekly income by 
the number of hours in the typical work week. Next, the 
number of hours missed in the last week because of one’s 
health (absenteeism) and the number of hours not produc-
tive in the last week because of health impairment while at 
work (presenteeism) were multiplied by the hourly rates to 
arrive at total lost wages for the week. These figures were 
then multiplied by the average number of work weeks in a 
year to obtain annual estimates. Finally, costs were divided 
by 12 to arrive at a PPPM estimate of indirect costs.
Analysis
The overall sample was analyzed by the level of SI. Patient 
demographic and clinical characteristics were assessed using 
descriptive statistics, using frequencies and percentages for 
categorical variables and means and standard deviations for 
continuous variables. Differences between the levels of SI 
groups were examined across all patient demographics, clin-
ical characteristics, and outcomes. For categorical variables, 
chi-square tests were used to determine significant differ-
ences while analysis of variance was used for continuous 
variables. The focal comparison was between patients with 
high SI and those with no SI.
Results
Patient Demographics
Among 75,000 respondents to the 2013 US NHWS, 11,456 
(15.3%) met the initial study inclusion criteria of a self- 
reported physician’s diagnosis of depression. From this 
group of patients, the analysis sample included the 2196 
patients who scored ≥15 on the PHQ-9 and screened negative 
on the MDQ (Figure 1). Among all patients with moderately 
severe or severe MDD, 68.0% reported any SI. Those report-
ing any level of SI were younger (p-values ≤0.05 for each SI 
severity group compared with the no SI group), and the 
proportion of males increased with increasing levels of SI 
(p’s ≤0.01 for each SI severity group compared with the no SI 
group; Table 1). Across SI groups, commercial insurance 
coverage was reported by 41% to 47% of patients; the high 
SI group had the largest proportion of uninsured patients 
(28%) compared with the other SI groups (Table 1).
Clinical Characteristics
Clinical characteristics, including BMI, smoking status, 
and number and types of comorbidities, were generally 
similar across groups (Table 2). A higher proportion of 
patients with moderate SI (30%) and high SI (29%) 
reported social anxiety as a mental health comorbidity 
compared with patients with no SI (22%; p’s ≤0.014; 
Table 2). The most commonly used medications across 
patient groups were selective serotonin reuptake inhibitors 
and/or serotonin-norepinephrine reuptake inhibitors 
(Appendix Figure 1a and 1b). Use of bupropion, antipsy-
chotics, and other medications was generally similar 
across SI groups; a higher proportion of patients with 
high SI (14%) and patients with moderate SI (12%) com-
pared with those with no SI (6%) reported taking antipsy-
chotics (p’s ≤0.005; Table 2).
Health-Related Quality of Life
Patients with high SI reported significantly lower mean 
SF-36v2 MCS scores compared with those with no SI 
(25.90 [SD=10.76] vs 29.01 [SD=9.25]; p <0.001; 
Table 3). Patients with high SI did not differ on their 
mean SF-36v2 PCS scores compared with those with no 
Figure 1 Analysis sample definition.  
Notes: Only employed patients are included in the calculation of the WPAI and 
indirect costs variables. HRU and direct cost outcomes include the full analysis sample. 
Abbreviations: NHWS, National Health and Wellness Survey; PHQ-9, Patient Health 
Questionnaire–9; MDQ, mood disorder questionnaire; SI, suicidal ideation; WPAI, Work 
Productivity Loss and Activity Impairment questionnaire; HRU, healthcare resource 
utilization.
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SI (p=0.796). Patients with high SI also reported signifi-
cantly lower mean SF-6D health utility index scores com-
pared with those with no SI (0.52 [SD=0.11] vs 0.54 
[SD=0.09]; p <0.001; Table 3).
Work Productivity and Activity 
Impairment and Indirect Costs
Among employed patients, work productivity was not 
statistically significant across all levels of SI (p=0.104); 
however, patients with high SI showed significantly higher 
work productivity loss (absenteeism and presenteeism 
combined; 45% vs 39%; p=0.039; Table 3) compared 
with those with no SI. For example, this would equate to 
18 hours of work productivity impairment per person 
compared with 15.6 impaired hours for an average 40- 
hour work week. Patients with high SI had higher activity 
impairment (60% vs 57%; p=0.087; Table 3) compared 
with those with no SI; however, this difference did not 
reach statistical significance. Patients with high SI incurred 
greater PPPM indirect costs ($1449 vs $1058; p=0.001; 
Table 3) compared with patients with no SI.
Healthcare Resource Utilization and 
Direct Costs
Patients with high SI reported significantly higher monthly 
rates of hospitalizations and ER visits compared with those 
with no SI (p’s <0.002; Table 3 and Figure 2), although 
there was no difference in HCP visits between these 
groups (p=0.679). Patients with high SI incurred greater 
PPPM direct costs ($1220 vs $796; p=0.002; Table 3) 
compared with those with no SI. Considering the total 
PPPM direct and indirect costs, monthly total costs for 
patients with high SI ($2475) were significantly higher 
than for those with no SI ($1714; p=0.010).
Discussion
To gain insights into the humanistic and economic burden 
of varying levels of SI in the context of MDD, we ana-
lyzed patients with moderately severe or severe MDD 
experiencing SI using the NHWS. Patients endorsing 
Item 9 of the PHQ-9, who comprised 2.0% of all NHWS 
respondents, were younger, more often male, and more 
often uninsured.
Health utilities observed in patients with high SI were 
significantly lower than in patients without SI. These utilities 
represent levels of overall HRQoL as low or lower than those 
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high SI had higher work productivity loss resulting in higher 
indirect costs compared with patients with no SI, which is 
unsurprising in the context of such low HRQoL. The results 
of this study showed most of the indirect cost was due to 
impairment at work (ie, presenteeism), suggesting that patients 
often show up to work despite the severity of their condition 
and demonstrate low productivity. The association between 
presenteeism and SI among patients with MDD is consistent 
with observations in a European population.39 Moreover, 
results from a previous study evaluating the relationship 
between depression symptoms and presenteeism have shown 
that cognitive symptoms accompanying depression, such as 
impaired concentration, anhedonia, and self-criticism, had a 
significant impact on presenteeism but were less important in 
predicting absenteeism.40 Using a multivariate model to com-
pare patterns and severity of self-reported productivity impair-
ment across several different medical conditions, depression 
was associated with the highest odds of problems with mental/ 
interpersonal functioning tasks and with overall output.41 A 
linear relationship has been demonstrated in the literature, with 
more severe depression symptoms correlated with increased 
presenteeism.40,42 Poor work adjustment may be an important 
risk factor for suicidal behavior in people with mood 
disorders.43 One study showed that while overall social adjust-
ment was not associated with suicide attempt history, indivi-
duals with poor work adjustment were significantly more 
likely to report a history of a suicide attempt.44
Among the patients with moderately severe or severe 
MDD in the current study, those with high SI had significantly 
higher rates of hospitalization and ER visits than those with no 
SI. While not all patients experience hospitalization or seek 
care, the cost of hospitalization accounted for the largest por-
tion of direct costs in this study. These results support previous 
studies showing the high impact of hospitalization on the 
economic burden associated with MDD and SI.7,45 In 2010, 
almost $100 billion of the estimated $210.5 billion economic 
burden of MDD in the US was attributable to direct medical 
costs, and $20.5 billion was due to inpatient medical services.7 
Data from the Agency for Healthcare Research and Quality 
reported that, in 2013, over 70% of emergency department 
(ED) visits related to SI resulted in admission or transfer to 
another hospital or facility compared with only 19% of all 
other ED visits.46 Among these SI-related ED visits that 
resulted in admissions, the aggregate cost of ED and inpatient 
care increased by 20% annually from 2006 to 2013.46
Such high HRQoL and economic burden highlight the 
need for effective screening and management of patients with 
MDD and SI. Considering the risk to these patients, it is 
important to note that several validated screening instruments 
to detect depression have been utilized in the primary care 
setting;47 however, challenges remain in identifying those at 
risk of suicidality.48,49 The PHQ-9 is a practical way to screen 
for and assess depression symptom severity in the real world 
given its inclusion in National Quality Forum (NQF)–endorsed 
quality measures, inclusion in Healthcare Effectiveness Data 
and Information Set (HEDIS) and Merit-based Incentive 
Payment System (MIPS) measures, and ease and frequency 
of use.24
Multiple health systems have published guidelines referen-
cing or endorsing the use of the PHQ-9 in the screening and 
management of depression. One example is Kaiser 
Permanente which published a guideline specifically including 
recommendations around screening and treatment based on the 
PHQ-9.50 The Department of Defense and Department of 
Veterans Affairs published joint guidelines recommending 
the use of the PHQ-9 for initial measurement of depression 
severity as well as treatment monitoring.51 These examples 
support the use of the PHQ-9 in depression screening, making 
this tool even more relevant to clinicians. With routine use, 
there is an opportunity to more effectively identify patients 
with MDD, and to better identify patients with SI, providing a 
chance for treatment and management of these at-risk 
individuals.
Limitations
Despite the insight that this study provides into the burden 
associated with SI in patients with moderately severe or severe 
MDD, several limitations should be considered. First, the data 
source used for this analysis was based on a cross-sectional 
Figure 2 Direct per patient per month costs by level of suicidal ideation and type of 
healthcare resource utilization among patients with moderately severe or severe MDD. 
Abbreviations: PPPM, per patient per month; US$, United States dollars; SI, 
suicidal ideation; ER, emergency room; HRU, healthcare resource utilization.
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study design that does not permit causal conclusions to be 
drawn. The data were collected from self-reports of patients 
responding to a survey conducted online, and thus responses 
may be subject to recall bias, could not be objectively con-
firmed through review of medical records (including diagnosis 
of MDD), and may overrepresent certain types of individuals 
who are more comfortable with online engagement. Of note, 
the instruments used in the data source did possess relatively 
short recall periods and thus should have limited the degree to 
which recall bias influenced study results. However, because 
the work productivity measure reports only the prior week’s 
functioning, we are unable to establish conclusions regarding 
long-term impact or association. Moreover, different outcome 
measures had varying recall periods (ie, 4 weeks for SF-36v2, 
7 days for WPAI, 6 months for HRU, and 2 weeks for the PHQ- 
9). Nevertheless, the results reported here trended as expected 
and were consistent with similar studies.6,7,16,39,45,46
The second limitation of this study was the absence 
of a clinical measure to categorize patients based on 
their level of SI. This analysis relied on using Item 9 
on the PHQ-9 to form the basis for assessing patients’ 
suicidal level in the analysis, as it has been associated 
with the risk of suicide.20,22,23 However, limitations may 
exist in the wording of this question. The PHQ-9 asks 
about the presence of either thoughts of being dead, 
without specifically asking about suicide (“you would 
be better off dead”), or thoughts of self-injury (“hurting 
yourself in some way”). Moreover, the range of 
responses, including “several days” and “more than 
half of the days”, may be confusing for respondents, 
particularly if they did not consider the appropriate 
recall period of 2 weeks.
Additional limitations include the non-random assign-
ment of patients based on their level of SI, which could 
lead to imbalances in risk factors between subpopulations 
and thus bias results. Since patients included in the ana-
lysis self-reported their physician diagnosed depression, 
the data do not provide codes to allow examination of 
specific depression subtypes. All combined, these limita-
tions may limit the comparability and generalizability of 
the results.
Conclusions
Higher levels of SI among patients with moderately severe or 
severe MDD were associated with significantly lower HRQoL, 
greater HRU, and greater work impairment resulting in higher 
direct and indirect costs compared with patients reporting no 
SI. These findings emphasize the importance of examining 
direct, indirect, and total costs for patients with MDD experi-
encing SI. Considering the increased HRQoL and economic 
burden among patients with moderately severe or severe MDD 
and high SI observed in this study, from the payer and 
employer perspectives, it is important to ensure these patients 
are identified and receive appropriate intervention to avoid 
further worsening of their SI levels and increased economic 
burden.
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